

RECEIVED
JUL 21 0 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Application No: 09/786,502
Filing Date: March 1, 2001
First Named Inventor: Sadelain
Group Art Unit:
Examiner Name:
Attorney Docket No.: MSK.P-040

Page 1 of 3

Examiner's Initials	US Patent Document	Name of Patentee or applicant of cited document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
------------------------	-----------------------	----------------------------------------------------	------------------------------------------	-----------------------------------------------------------------------------

FOREIGN PATENT DOCUMENTS


Examiner's Initials	Cite No.	office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear	T ⁶
Art	1	WO	96/24676		Whitehead Institute for Biomedical Research	August 1996		

Anne L. Sullivan 2/2/03

RECEIVED


JUL 20 2001

TECH CENTER 1600-2900



Examiner Initials	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
A2H	Ko-Jiunn Liu et al., "Identification of Rat Prostatic Steroid-Binding Protein as Target Antigen of Experimental Autoimmune Prostatitis" Journal of Immunology, 159: 472-480 (1997)
A2H	Bao-Hua Xue et al., "Induction of Human Cytotoxic T Lymphocytes Specific for Prostate-Specific Antigen" Prostate, 30:73-78 (1997)
A2H	Cheryl J. Fitzer-Attas et al., "Harnessing Syk Family Tyrosine Kinases as Signaling Domains for Chimeric Single Chain of the Variable Domain Receptors: Optimal Design for T Cell Activation" Journal of Immunology, 160:145-154 (1998)
A2H	H.F. Gallardo et al., "Recombinant Retroviruses Pseudotyped With the Vesicular Stomatitis Virus G Glycoprotein Mediate Both Stable Gene Transfer and Pseudotransduction in Human Peripheral Blood Lymphocytes." Blood, 90 : 952-957 (1997)
A2H	Phillip K. Darcy et al., "Expression in cytotoxic T lymphocytes of a single chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma" Eur. J. Immunol., 28:1663-1672 (1998)
A2H	Michael C. Gong et al., "Cancer Patient T Cells Genetically Targeted to Prostate-Specific Membrane Antigen Specifically Lyse Prostate Cancer Cells and Release Cytokines in Response to Prostate-Specific Membrane Antigen" Neoplasia, 1:123-127 (1999)
A2H	Anja Krause et al., "Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes." J. Exp. Med, 188: 1-8 (1998)
A2H	Michael L. Salgaller et al., "Report of Immune Monitoring of Prostate Cancer Patients Undergoing T-Cell Therapy Using Dendritic Cells Pulsed With HLS-A2-Specific Peptides From Prostate-Specific Membrane Antigen (PSMA) The Prostate, 35:144-151 (1998)
A2H	G. Murphy et al., "Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed With HLS=A0201-Specific Peptides from Prostate-Specific Membrane Antigen" The Prostate, 29:371-380 (1996)
A2H	Dirk Lindemann et al., "Versatile Retrovirus Vector Systems for Regulated Gene Expression in Vitro and In Vivo" Molecular Medicine, 3:466-476 (1997)

Anne L. Halleran 2/7/03



JCH	S.J. Simmons et al., "GM-CSF as a Systemic Adjuvant in a Phase II Prostate Cancer Vaccine Trial" The Prostate, 39:291-297 (1999)
JCH	Gilda G. Hillman et al., "Prospects of Immunotherapy for the Treatment of Prostate Carcinoma-A Review" Cancer Detection and Prevention, 23:333-342 (1999)

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Anne Hillman Date Considered 2/8/03



COPY OF PAPERS
ORIGINALLY FILED

Substitute for form 1449

Application No.: 09/786,502

Applicant: Sadelain, et al.

Filing Date: March 2, 2001

Title: Fusion Receptors Specific for
Prostate-Specific Membrane
Antigen and Uses Thereof

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

RECEIVED

JUN 14 2002

Page 1 of

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
Alt	5686281	Roberts	11 Nov 1997

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Signature

Date Considered

Ann L. Hillman

2/7/03



COPIES OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 23 2002

Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No.: 09/786,750 TECH CENTER 1600/2900

Applicant: Sadelain et al.

Filing Date: May 18, 2001

Conf. No.: 1539

Title: Fusion Receptors Specific for
Human Prostate-Specific
Membrane Antigen and Uses
Thereof

Attorney Docket No.: MSK.P-040

Page 1 of 1

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
Alt.	Alvarez-Vallina L. et al., "Antigen-Specific Targeting of CD28-Mediated T Cell Co-Stimulation using Chimeric Single-Chain Antibody Variable Fragment - CD28 Receptors", <i>European Journal of Immunology</i> , Vol. 26, No. 1(1995) pp. 2304-2309 XP000646504
Alt	Moritz D. et al., "A Spacer Region Between the Single Chain Antibody and the CD3 KSI-Chain domain of Chimeric T Cell Receptor Components is Required for Efficient Ligand Binding and Signaling Activity", <i>Gene Therapy</i> , vo. 2, No. 8 (1995) pp. 539-546 XP000674790
Alt	Tran A-C et al., "Chimeric Dzeta-Receptors Direct Human Natural Kill (NK) Effector Function to Permit Killing of NK-Resistant Tumor Cells and HIV-Infected T Lymphocytes", <i>Journal of Immunology</i> , Vol. 155, No. 2, pp. 1000-1009 XP000882943 1995

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Anne L. Holleran
Examiner Signature

2/7/03
Date Considered